Clinical Trial Update: Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating nine weeks of treatment with 683699 in patients with moderately to severely active Crohn's disease; the study status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• 683699

Snippet

Sponsor: GlaxoSmithKline | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED